Exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-002266-40

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate flow mediated dilation (FMD) by Doppler ultrasound at week 12 in subjects in treatment arm A (300 mg Secukinumab) compared to the pooled group of patients in treatment arms C and D (placebo up to week 12).


Critère d'inclusion

  • active chronic plaque-type psoriasis

Liens